News
At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not ...
An FDA panel meeting featured a heated dialogue over whether fluoride supplements could pose health risks to children. Here's ...
The FDA is spreading lies about medications people need—and starting their attack by targeting pregnant women.
An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...
Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ ...
Bypassing its standard pathways for scientific discussions, FDA has recently held a slew of so-called "expert panels" that ...
The FDA may remove the warning labels on hormone replacement therapies used to treat the symptoms of menopause. Doctors say ...
The FDA may remove the warning labels on hormone replacement therapies used to treat the symptoms of menopause. Doctors say ...
The five centers set to close have served over 22,000 patients in the past year, many of whom are low-income with few ...
The Vancouver Sun on MSN17h
Member of B.C. health committee who resigned over rare disease drug funding alleges political interferenceA member of a B.C. committee who abruptly resigned last week after the province reinstated drug funding for a girl with a ...
Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...
On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback